Dataset from A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema

The primary objective of the study is to determine if treatment with high-dose aflibercept (HD) at intervals of 12 or 16 weeks provides non-inferior best corrected visual acuity (BCVA) compared to aflibercept dosed every 8 weeks.The secondary objectives of the study are as follows:* To determine the effect of HD vs. aflibercept on anatomic and other visual measures of response* To evaluate the safety, immunogenicity, and pharmacokinetics (PK) of aflibercept